Clinical Analysis of Preoperative Neoadjuvant Chemotherapy by Thalidomide Combined with Gefitinib for Non-small Cell Lung Cancer
10.3969/j.issn.1003-4706.2016.01.015
- VernacularTitle:沙利度胺联合吉非替尼新辅助化疗对非小细胞肺癌的临床价值
- Author:
Xiao-Hong XU
1
;
Jia-Bin CHEN
;
Yin-Wen XIA
;
Jun-Shan RUAN
Author Information
1. 汉川市人民医院
- Keywords:
Thalidomide;
Gefitinib;
Neoadjuvant chemotherapy;
NSCLC
- From:
Journal of Kunming Medical University
2016;37(1):65-68
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical effect of preoperative neoadjuvant chemotherapy by thalidomide combined with gefitinib for non-small cell lung cancer (NSCLC) patients and provide clinical basis for NSCLC therapy.Methods From 2011/1 to 2013/1,we collected 160 NSCLC cases in our hospital and divided them into 2 groups randomly,80 cases in control group and 80 cases in observation group.The patients in the control group were treated with conventional surgical treatment and patients in the observation group were treated with preoperative neoadjuvant chemotherapy by thalidomide combined with gefitinib before surgery.The clinical effects,the 6 months and 1 year survival rates,and the toxicity effects were observed,and the clinical effects and survival rates between the 2 groups were compared.Results The observation group had a therapeutic efficiency ratio (TER) of 80.0％ which was significantly higher than the control group (50.0％),and the difference was statistically significant (P＜0.05).The 6 months survival rate and 1 year survival rate were 97.5％ and 92.5％,which were both significantly higher than those of control group (87.5％ and 77.5％),and all differences were statistically significant (P＜0.05).The toxicity effects of observation group were lower.Conclusions Preoperative neoadjuvant chemotherapy by thalidomide combined with gefitinib for NSCLC therapy is effective and safe,which is worthy of study and further application in clinical treatment..
